Free Trial
NASDAQ:XBIO

Xenetic Biosciences Q1 2023 Earnings Report

Xenetic Biosciences logo
$3.10 +0.21 (+7.27%)
Closing price 05/6/2025 03:58 PM Eastern
Extended Trading
$3.20 +0.11 (+3.39%)
As of 05/6/2025 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Xenetic Biosciences EPS Results

Actual EPS
-$0.60
Consensus EPS
-$1.10
Beat/Miss
Beat by +$0.50
One Year Ago EPS
N/A

Xenetic Biosciences Revenue Results

Actual Revenue
$0.61 million
Expected Revenue
$0.41 million
Beat/Miss
Beat by +$200.00 thousand
YoY Revenue Growth
N/A

Xenetic Biosciences Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Thursday, May 11, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

Xenetic Biosciences' Q1 2025 earnings is scheduled for Thursday, May 8, 2025

Xenetic Biosciences Earnings Headlines

Xenetic Biosciences (XBIO) Receives a Hold from H.C. Wainwright
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
Xenetic Biosciences Inc
3XB0.SG,0P0001N0OC,0 (3XB0.SG)
See More Xenetic Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email.

About Xenetic Biosciences

Xenetic Biosciences (NASDAQ:XBIO), Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

View Xenetic Biosciences Profile

More Earnings Resources from MarketBeat